You are here: Industry Insights > Valneva

News List

Valneva and Pfizer report further positive Phase 2 data for Lyme disease vaccine candidate WorldPharmaNews
February 07, 2022
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. (NYSE: PFE) today reported further positive Phase 2 data for their Lyme disease vaccine candidate, VLA15.
Valneva & Pfizer Report Phase 2 Data for Lyme Disease Vaccine Candidate contractpharma
February 03, 2022
Plan to proceed with a three-dose primary series vaccination schedule in a planned Phase 3 clinical trial.
Valneva Signs Advance Purchase Agreement with Bahrain for Inactivated COVID-19 Vaccine VLA2001 AmericanPharmaceuticalReview
December 09, 2021
Valneva SE announced the signing of an advance purchase agreement with the Kingdom of Bahrain for the supply of one million doses of the Company’s inactivated COVID-19 vaccine candidate VLA2001. This is the second purchase agreement Valneva has secured...
EMA begins rolling review of Valneva’s Covid-19 vaccine candidate VLA2001 Pharmaceutical-Business-Review
December 06, 2021
Valneva stated that it is now focused on securing regulatory approvals for VLA2001 after the positive results from the Phase III trial.
Valneva, IDT Biologika partner to produce Covid-19 vaccines Pharmaceutical-Business-Review
December 01, 2021
French company Valneva and IDT Biologika have partnered to manufacture the former’s inactivated vaccine candidate, VLA2001, for Covid-19.
Valneva, IDT Biologika Enter COVID Vax Mfg. Pact ContractPharma
November 30, 2021
Valneva SE, a specialty Vaccine company, and IDT Biologika have entered a collaboration for the production of Valneva’s inactivated COVID-19 vaccine candidate VLA2001. This follows last week’s announcement...
Valneva Inks APA with European Commission for COVID Vax ContractPharma
November 24, 2021
Valneva SE, a specialty Vaccine company, has signed an Advance Purchase Agreement (APA) with the European Commission (EC) to supply up to 60 million doses of its inactivated COVID-19 vaccine candidate...
Valneva to supply Covid-19 vaccine doses to EU Pharmaceutical-Business-Review
November 12, 2021
French company Valneva has received European Commission (EC) approval for an agreement to supply the company’s inactivated Covid-19 vaccine candidate, VLA2001.
EC to procure 60 million doses of Valneva’s Covid-19 vaccine Pharmaceutical-Technology
November 12, 2021
The European Commission (EC) has approved an agreement to purchase up to 60 million doses of the Valneva inactivated vaccine candidate VLA2001 for Covid-19 over a period of two years.
Further clinical trial planned for Valneva’s COVID-19 vaccine candidate pharmatimes
August 13, 2021
Valneva is planning to initiate a further Phase III trial (VLA2001-304) for its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001.

Previous page 1 2 3 4 5 Next page